Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer
International Journal of Cancer · 03.11.2026
DOI: 10.1002/ijc.70806 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 03.11.2026. Verfasst von Qiyu Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, National Natural Science Foundation of China, Beijing Bethune Charitable Foundation.
Abstract (Originalsprache)
Intraductal carcinoma of the prostate (IDC‐P) has been associated with increased homologous recombination deficiency (HRD). We evaluated the association between IDC‐P and the efficacy of olaparib plus novel hormonal therapy (NHT) in metastatic castration‐resistant prostate cancer (mCRPC) after progression on prior NHT. A total of 64 consecutive patients were analyzed, including 33 with IDC‐P and 31 with prostate adenocarcinoma (PAC). An external validation cohort of 36 patients from two additional centers was also included. Primary outcomes were progression‐free survival (PFS), while treatment‐change free survival (TFS), prostate‐specific antigen response, overall survival, and adverse events were additionally assessed. After a median follow‐up of 35.0 months, IDC‐P was associated with longer PFS and TFS than PAC (PFS, 6.2 vs. 3.0 months; TFS, 10.0 vs. 6.3 months; both p < 0.01). This association remained significant in patients with BRCA1/2 mutations and after multivariable adjustment for BRCA1/2 mutation status. In the validation cohort, IDC‐P status was associated with longer PFS (6.1 vs. 3.1 months, p = 0.02). In an independent cohort of 187 patients with prostate cancer, IDC‐P was associated with higher HRD scores than PAC in the BRCA1/2‐mutated subgroup, with a nonsignificant trend in the BRCA1/2‐wild‐type subgroup, suggesting a possible biological context for the observed outcome association. These findings suggest that IDC‐P may serve as a practical pathological biomarker associated with improved outcomes following PARP inhibitor‐based therapy in mCRPC, although further large‐scale prospective validation is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Urology, Institute of Urology, West China Tianfu Hospital, Sichuan University, Chengdu, China.
Förderung
- West China Hospital, Sichuan University
- National Natural Science Foundation of China
- Beijing Bethune Charitable Foundation
- Science and Technology Department of Sichuan Province
- Special Research Fund for Radionuclide Diagnosis and Therapy of Prostate Cancer
- China National Nuclear Corporation
Zitieren
APA
Zhu, Q., Wang, L., Chen, J., Zhou, X., Tan, Z., Guo, J., Liu, H., Nie, L., Chen, N., Shen, P., Liu, Z., Zeng, H., & Zhao, J. (2026). Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70806
Vancouver
Zhu Q, Wang L, Chen J, Zhou X, Tan Z, Guo J, et al. Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70806
BibTeX
@article{Zhu2026,
author = {Zhu, Qiyu and Wang, Ling and Chen, Junru and Zhou, Xiuya and Tan, Zehua and Guo, Jingjing and Liu, Haoyang and Nie, Ling and Chen, Ni and Shen, Pengfei and Liu, Zhenhua and Zeng, Hao and Zhao, Jinge},
title = {Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70806}
}
EUVIMED